Free Republic
Browse · Search
General/Chat
Topics · Post Article

Skip to comments.

Clinical trial sets stage for new paradigm in kidney cancer treatment (90% metastatic kidney cancer control at one year)
Medical Xpress / UT Southwestern Medical Center / European Urology Oncology ^ | August 19, 2022 | Raquibul Hannan et al

Posted on 08/20/2022 8:54:18 PM PDT by ConservativeMind

Kidney cancer encompasses a wide spectrum and can present with extensive metastases or just a handful. However, today all patients are treated the same. They all receive medication.

Investigators report the results of a clinical trial exploring the role of stereotactic ablative radiation therapy (SAbR) for patients with a handful of metastases, or so-called oligometastatic disease. The study represents the first clinical trial for patients with untreated oligometastatic kidney cancer.

Each year brings more than 430,000 new cases of kidney cancer worldwide and nearly 180,000 deaths, according to the World Health Organization. About 40% of patients develop metastatic disease. Metastatic kidney cancer is typically treated with immunotherapy agents or targeted drugs, which are toxic and diminish quality of life. For most patients, the disease ultimately progresses, necessitating a change in treatment, until patients exhaust their options. When metastatic, most patients eventually succumb to the disease, and the quality of their remaining time is undermined by the cancer drugs.

The phase 2 clinical trial tested SAbR, a treatment that delivers potent, narrow beams of radiation to tumors, in 23 kidney cancer patients with oligometastases (up to five metastases) at UT Southwestern and the affiliated county hospital, Parkland Health. Patients received SAbR to metastatic tumors at the outset and while the disease remained oligometastatic. Overall, 57 metastases were treated. The primary goal was to control the metastatic cancer in at least 60% of patients at one year. The study was successful with more than 90% of patients with disease control at one year without systemic therapy.

"It appears that most patients will be free of systemic therapy for at least two years," said Dr. Hannan.

None of the patients experienced serious side effects, and periodic questionnaires showed no negative impact on quality of life.

(Excerpt) Read more at medicalxpress.com ...


TOPICS: Health/Medicine
KEYWORDS: kidneydisease; metabolism; sabr; stereotactic
This is available today, but generally used for other cancers.

No serious side effects and no negative impact on quality of life.

1 posted on 08/20/2022 8:54:18 PM PDT by ConservativeMind
[ Post Reply | Private Reply | View Replies]

To: Pete from Shawnee Mission; Mazey; ckilmer; goodnesswins; Jane Long; BusterDog; jy8z; ...

The “Take Charge Of Your Health” Ping List

This high volume ping list is for health articles and studies which describe something you or your doctor, when informed, may be able to immediately implement for your benefit.

Email me to get on either the “Common/Top Issues” (20% fewer pings) or “Everything” list.

2 posted on 08/20/2022 8:55:05 PM PDT by ConservativeMind (Trump: Befuddling Democrats, Republicans, and the Media for the benefit of the US and all mankind.)
[ Post Reply | Private Reply | To 1 | View Replies]

To: ConservativeMind

That’s good news.

My brother died of kidney cancer at 32. At least they thought it started in his kidneys. Very low prognosis back then.


3 posted on 08/20/2022 9:11:12 PM PDT by DannyTN
[ Post Reply | Private Reply | To 1 | View Replies]

Disclaimer: Opinions posted on Free Republic are those of the individual posters and do not necessarily represent the opinion of Free Republic or its management. All materials posted herein are protected by copyright law and the exemption for fair use of copyrighted works.

Free Republic
Browse · Search
General/Chat
Topics · Post Article

FreeRepublic, LLC, PO BOX 9771, FRESNO, CA 93794
FreeRepublic.com is powered by software copyright 2000-2008 John Robinson